Hormone receptor positive breast cancer

23 trials 9 recruiting MedDRA PT
23 Registered trials
9 Recruiting
18 Unique sponsors
24 Unique IMPs
17 Commercial trials
Drug classes (ATC)
— ATC code not specified 12
L Oncology (ATC L) 10
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
CDK inhibitor 3 substances
SERD 2 substances
Taxane 2 substances
Antibody-drug conjugate (ADC) 2 substances
Corticosteroid 1 substance
Antimetabolite 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Kinase inhibitor 1 substance
Anthracycline 1 substance
Monoclonal antibody 1 substance
Phase III: 11 Phase II: 3 Phase I/II: 1 Phase IV: 2 Phase I: 3 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 23 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 23 trials

Phase III

11 trials
  • Celcuity Inc. Commercial
    ALPELISIB; DEXAMETHASONE; FULVESTRANT; GEDATOLISIB; PALBOCICLIB
    2022-502145-10-00 12 countries 2023 n=233
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ALPELISIB; ALPELISIB, ALPELISIB; INAVOLISIB
    2022-502322-41-00 6 countries 2023 n=150
    Ended
  • Gilead Sciences Inc. Commercial
    CAPECITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; SACITUZUMAB GOVITECAN
    2022-502593-17-00 11 countries 2023 n=428
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-504918-29-00 16 countries 2024 n=438
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN
    2025-520582-51-00 7 countries 2025 n=211
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    IMP not specified
    2023-509242-35-00 3 countries 2020 n=1,624
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    RIBOCICLIB
    2024-515769-32-00 1 country 2019 n=1,684
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    ELACESTRANT; RIBOCICLIB
    2025-522484-15-00 3 countries 2026 n=1,520
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    PALBOCICLIB
    2024-510776-20-00 5 countries 2019 n=381
    Ended
  • Reinier de Graaf Groep Academic
    IMP not specified
    2023-507847-13-00 1 country 2024 n=67
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Academic
    CAPIVASERTIB
    2024-511392-15-00 3 countries 2025 n=250
    Recruiting

Phase II

3 trials
  • Medica Scientia Innovation Research S.L. Commercial
    CAMIZESTRANT
    2024-520027-88-00 2 countries 2026 n=131
    Recruiting
  • Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic
    LOPERAMIDE HYDROCHLORIDE
    2024-514630-21-00 4 countries 2022 n=175
    Ended
  • Institut Jules Bordet Academic
    DOXORUBICIN HYDROCHLORIDE; OLECLUMAB; PACLITAXEL
    2024-511849-19-00 2 countries 2019 n=147
    Ended

Phase I/II

1 trial
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended

Phase IV

2 trials
  • GE Healthcare Limited Commercial
    IMP not specified
    2024-517400-11-00 1 country 2024 n=165
    Ended
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2022-500764-35-00 1 country 2022 n=2,000
    Recruiting

Phase I

3 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • Exelixis Inc. Commercial
    IMP not specified
    2024-515617-18-00 5 countries 2022 n=140
    Ended

Phase I (Other)

2 trials
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended
  • Laboratorios Farmaceuticos Rovi S.A. Commercial
    IMP not specified
    2025-523269-31-00 1 country 2026 n=57
    Recruiting

Phase I (First in Human)

1 trial
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
WSG Westdeutsche Studiengruppe GmbH Commercial 4 Phase III 2
Exelixis Inc. Commercial 2 Phase I, Phase I (Other) 0
Merck Sharp & Dohme LLC Commercial 2 Phase III 2
Beigene Ltd. Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 1
Laboratorios Farmaceuticos Rovi S.A. Commercial 1 Phase I (Other) 1
Medica Scientia Innovation Research S.L. Commercial 1 Phase II 1
Celcuity Inc. Commercial 1 Phase III 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Gilead Sciences Inc. Commercial 1 Phase III 0
GE Healthcare Limited Commercial 1 Phase IV 0
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 0
Cyclacel Limited Commercial 1 Phase I/II 0
Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic 1 Phase II 0
Institut Jules Bordet Academic 1 Phase II 0
ETOP IBCSG Partners Foundation Academic 1 Phase III 0
Reinier de Graaf Groep Academic 1 Phase III 1
Institut fuer Frauengesundheit GmbH Academic 1 Phase IV 1
New trials by year
2019
3
2020
1
2022
5
2023
4
2024
5
2025
2
2026
3
← All indication landscapes